NL-OMON40187已完成不适用
Beat-It: A pilot study on the practicality and effectiveness of a m-health application in improving emotion regulation in adolescents with externalizing disorder. - Beat-It
Yulius0 个研究点目标入组 26 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 17（—）
入选标准
- •1. All adolescents included in the study will be from 12 to 18 years of age.
- •2. All adolescents must have an official DSM-IV diagnosis ADHD, ODD or CD.
- •3. Adolescent are in the possesion of a smartphone with an Android based operating system. Suitable smartphones are made by Samsung, HTC, Huawei, Motorola, LG, Sony Ericsson en Acer. For a complete overview of suitable smartphones please check appendix K6 of the protocol.
- •4. Minimum total intelligence score must be 70. If the total intelligence score is not known, had been established by a non-COTAN approved test or has been performed more than to years previous to the start of the intervention, total intelligence score will be established using the short version of the Wechsler Intelligence Scale for Children third version (WISC-III-NL, Wechsler, 2005) for the adolescents younger than 16 years. If the adolescent is 16 years of age or older, the total intelligence score will be established using the short version of the Wechsler Adult Intelligence Scale * fourt edition * Dutch version (WAIS-IV-NL, Wechsler, 2012).
- •5. Both adolescents and at least one of the parents/legal guardians must have a reasonable understanding of the Dutch language.
- •6. Adolescents can only be included after a written informed consent has been signed by both parents or legal guardians and adolescents. It is important that parents and adolescents understand the information and are able to fill out the consent form.
- •7. During the intervention all medication used by the adolescent is permitted.
- •8. A score within the clinical range of the SDQ (parent version) has to be met.
排除标准
- •1. Adolescent with Axis-I disorders other than the discribed disorders will be excluded.
- •2. Adolescent who are not in the posession of or do not have acces to an android based smartphone can not be included.
研究者
相似试验
已完成
2 期
An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleedingRendu-Osler-Weber and Hereditary hemorrhagic telangiectasia10017959NL-OMON43279Maag-, darm- en leverziekten11
已完成
4 期
An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settingsfactor VIII deficiency1006447710005330Hemophilia ANL-OMON39506Pfizer1
已完成
2 期
A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adultsonbehandelbare en/of terugkerende vorm van kanker: leukemie, hoogradig glioom, neuroblastoom, sarcoomrelapsed or refractory cancer10027655NL-OMON49172Cancer Research UK Clinical Trials Unit4
已完成
不适用
A prospective, multi-centre study investigating the incidence and prognosis of relapses, pseudo-relapses and other causes of (sub)acute neurological symptoms in patients with relapsing-remitting multiple sclerosis.Multiple sclerosisNL-OMON55562Sint Elisabeth Ziekenhuis125
已完成
不适用
A First in Humans Study of Safety and Feasibility of baroloop: The baroloop Study10057166hypertensionNL-OMON54976neuroloop GmbH6